In addition to traditional surgical treatment, radiotherapy and chemotherapy and targeted therapy, cellular immunotherapy is the most powerful and meaningful treatment method at present. Many patients with advanced solid cancer, when all other therapies fail, will try cellular immunotherapy as the last blow to cancer cells as long as their economic ability allows.

The higher the tumor mutation load, the better the immunotherapy effect. However, not everyone can successfully defeat tumor cells after cellular immunotherapy. Recently, a study supported by the National Natural Science Foundation collected more than 600 papers and selected 45 experiments. The number of participants in the experiment exceeded1030,000. The results show that there is a tumor mutation load (TMB) in cancer patients. The results of this study have been published in the journal Tumor Immunology.

In this study, the research team listed lung cancer, melanoma, multiple myeloma, breast cancer and other cancers as research objects. After analyzing the samples of 654.38+10,000 people who participated in the experiment, it is concluded that the tumor mutation load (TMB) in vivo is positively correlated with the survival rate of patients, and the value range of high TMB is 3.3-203.

Why is the higher the TMB value, the better the effect of immunotherapy? The higher the TMB value in patients, the easier it is to produce abnormal proteins, which look different from normal cells and are easier for immune cells to recognize. When immune cells are activated by immunotherapy, the higher the TMB, the better the therapeutic effect of immunotherapy.

No matter what kind of cancer, the higher the TMB value, the better the curative effect of immunotherapy. It is worth noting that this study also included various cancers in the experimental analysis. The results show that the overall survival rate of patients with melanoma, lung cancer or other cancer types, no matter what kind of cancer, is significantly prolonged. Therefore, in order to achieve good cancer treatment effect through immunotherapy, it is necessary to see whether the TMB value in patients is high enough.

The results of this study confirmed that "tumor mutation load" (TMB) is a general biological index to predict the efficacy of immunotherapy, and TMB has become another important predictive index to confirm the efficacy of immunotherapy after PD-L 1. However, the research team found no correlation between TMB and PD-L 1. In other words, when the TMB value is high, the amount of PD-L 1 in the body is not necessarily high.